Ilyang to file health registration for Ilaprazole in China.

Ilyang is conducting a phase III clinical study on Ilaprazole, a new anti-peptic ulcer drug, in China, and intends to apply its NDA probably around February next year for the market launching in the late 2006 under the technical license agreement with Livzon of China.

The peptic ulcer drug markets in China showed over 30% growth every year and the market volume of H2 receptor and PPI marke...